CDX2 and breast carcinoma: Furthermore, we explored the association between Cdx2 polymorphism and VDR immunohistochemical expression in an ad hoc retrospective series of 80 human breast carcinomas taking into account breast cancer molecular classification (Luminal A, Luminal B, HER2-Subtype (HS), and Triple Negative) and clinical-pathological parameters routinely detected in breast cancer management.